SWSuzanne E. Wardell

Suzanne E. Wardell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suzanne E. Wardell has a total of 217 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estrogen promotes tumor phenotypes in ER+ and ER– breast cancer through UGDH-GPR30

    by Meghan J. Price, Annee D. Nguyen, Corinne H. Strawser, Trupti Trivedi, Cesar C.D. Baeta, Catherine Lavau, Jovita K. Byemerwa, Debarati Mukherjee, Suzanne E. Wardell, Sandeep Artham, et al.

    Estrogen can promote aggressive tumor phenotypes in estrogen receptor–positive (ER + ) breast cancer; however, ER – cell lines are not widely considered estrogen responsive. Noncanonical estrogen-stimulated pathways such as the membrane-bound G protein–coupled estrogen receptor ( GPR30 ) can mediate migratory and proliferative phenotypes in breast cancer and are postulated to promote resistance to aromatase therapies. Moreover, dysregulation of UDP-glucose 6-dehydrogenase ( UGDH ), a ubiquitously expressed enzyme critical to the metabolism of UDP-glucuronic acid into extracellular matrix precursors and hormone regulation, is associated with tumorigenesis. Here, we illustrated the impact of estrogen stimulation on tumor phenotypes in ER + and ER – cell models in vitro and in vivo. We then demonstrated UGDH ’s association with metastatic breast cancer via single-cell sequencing of patient specimens. Genetic knockdown of UGDH blunted estrogen-stimulated tumor phenotypes in vitro, ex vivo, and in vivo using both ER + and ER – breast cancer lines. Finally, we demonstrated that UGDH knockdown blunted noncanonical estrogen stimulation through GPR30 . Ultimately, our study validated prior studies demonstrating estrogen-responsive malignant phenotypes in ER – breast cancer and demonstrated that estrogen-stimulated breast cancer progression can be mediated through noncanonical pathways (e.g., UGDH/GPR30 ), regardless of ER status.

  • Open Access

    Supplemental Tables 1-7 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State

    by Shane T. Killarney, Gabriel Mesa, Rachel Washart, Benjamin Mayro, Kerry Dillon, Suzanne E. Wardell, Madeline Newlin, Min Lu, Areej Abu Rmaileh, Nicky Liu, et al.

    - Table 1: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score for all solid tumor cell lines in DepMap, excluding sarcomas - Table 2: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score and ssGSEA EMT Enrichment score vs mRNA Expression for all solid tumor cell lines in DepMap, excluding sarcomas - Table 3: Results of the Quantitative Phosphoproteomics experiment of Kinase Active (KA) vs Kinase Dead (KD) PKN2 expressing 293FT cells - Table 4: Candidate list of direct PKN2 substrates -Table 5: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Protein Abundance for all patient tumors in CPTAC - Table 6: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Phosphoprotein Abundance for all patient tumors in CPTAC - Table 7: Substrate Signatures used for CPTAC Kinase Enrichment Analysis

  • Open Access

    Supplementary Figures S1-S4 from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State

    by Shane T. Killarney, Gabriel Mesa, Rachel Washart, Benjamin Mayro, Kerry Dillon, Suzanne E. Wardell, Madeline Newlin, Min Lu, Areej Abu Rmaileh, Nicky Liu, et al.

    -Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.

  • Open Access

    Data from PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State

    by Shane T. Killarney, Gabriel Mesa, Rachel Washart, Benjamin Mayro, Kerry Dillon, Suzanne E. Wardell, Madeline Newlin, Min Lu, Areej Abu Rmaileh, Nicky Liu, et al.

    Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts.Significance:This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts.See related commentary by Shen and Tan, p. 458

  • Open Access

    Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

    by Jianhui Ma, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Mark R. Lackner, et al.

    Supplementary Figure S4 shows Combination of ZN-c5 and palbociclib further arrests the cells at G1 phase A. Relative ER level to DMSO after normalized to β-actin control for Figure 4B. B. MCF-7 cells were treated with 500nM of palbociclib for indicated time, cyclin D1 and p-Rb expression were examined by western blot. C. MCF-7 cells were treated with 100nM ZN-c5 or fulvestrant, 500nM palbociclib, or combination of palbociclib with ZN-c5 or fulvestrant, for 24 hours. Western blot analysis of cyclin D1, pRb, ERα and PR were performed. D. cell cycle analysis of MCF-7 cells treated with ZN-c5 or palbociclib for 48 hours.

  • Open Access

    Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

    by Jianhui Ma, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Mark R. Lackner, et al.

    Supplementary Table S3 shows The effect of ZN-c5 and tamoxifen on E2-induced genes

  • Open Access

    Data from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

    by Jianhui Ma, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Mark R. Lackner, et al.

    Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER+/HER2−) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER-targeting therapies. Fulvestrant, a selective ER degrader (SERD) that antagonizes and degrades ER simultaneously, has demonstrated activity in ER+/HER2− breast cancers the ability to overcome endocrine resistance. Fulvestrant has limitations, including challenging administration by intramuscular injection and poor bioavailability, resulting in suboptimal drug exposure; hence, several next-generation oral SERDs with improved drug properties have been developed and are currently being evaluated in the clinic for their therapeutic benefit. In this study, we describe the discovery of ZN-c5, an orally bioavailable SERD with favorable pharmacokinetic properties and potent activities against both wild-type and mutant ER. In vivo studies showed that ZN-c5 treatment resulted in significant tumor growth inhibition in a variety of breast cancer models and patient-derived xenograft models that harbor ESR1 mutations. Combination with CDK4/6 inhibitors or PI3K pathway inhibition enhanced antitumor effects compared with single-agent alone. ZN-c5 also demonstrated bone-protective effect as observed in a mouse osteoporosis model. These data support the clinical utility of ZN-c5 as monotherapy and as a combination therapy for patients with ER+/HER2− breast cancers. Although encouraging plasma exposure and tolerability have been observed for ZN-c5 in patients, further studies are needed to optimize its therapeutic efficacy.

  • Open Access

    Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

    by Jianhui Ma, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Mark R. Lackner, et al.

    Supplementary Table S4 shows The effect of ZN-c5 and tamoxifen on E2-suppressed genes

  • Open Access

    Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

    by Jianhui Ma, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Mark R. Lackner, et al.

    Supplementary Figure S1 shows ZN-c5 is a novel SERD that inhibits growth of ER + tumors in vitro and in vivo A. ERα degradation curve after ZN-c5 treatment and DC50 (concentration at 50% degradation) determination for Figure 1B top; B. Top: western blot analysis of ERα degradation at 24 hours after fulvestrant treatment in MCF-7 cells at indicated concentration; Bottom: ERα degradation curve and DC50 determination for fulvestrant; C. Tumor growth curve of MCF-7 xenograft model. Mice bearing MCF-7 tumor cells were dosed orally once a day for 26 days. D&E, body weight changes after ZN-c5 or fulvestrant treatment.

  • Open Access

    Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

    by Jianhui Ma, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Mark R. Lackner, et al.

    Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after treatment with 0.1nM E2, 100nM ZN-c5 or 100nM fulvestrant. C. Western blot analysis of ER and PR protein after different concentrations of ZN-c5 treatment for the indicated time in MCF7 ERY537S heterozygous cells. ER or PR protein change (%) relative to non-treatment control after correction by GAPDH. D. WHIM20 tumor bearing mice were dosed with ZN-c5 or fulvestrant at PR protein level in WHIM20 tumor samples harvested at the end of an efficacy study. ZN-c5 was dosed at 40mg/kg, fulvestrant was dosed at 5mg/dose. E. ER expression in WHIM20 tumors by immunohistochemistry (IHC) at the end of efficacy study